儿科肝母细胞瘤的死亡率趋势:巴西和全球视角
Raquel Francine Liermann Garcia1,2,3, Camila Barbosa1,3, José Guilherme Pickler1,2
1Department of Scientific Development and Innovation (DECIPE), Center for Anatomo-Pathological Diagnosis (CEDAP), Joinville 89201-330, SC, Brazil.
Cancers
|September 27, 2025
概括
肝母细胞瘤是一种罕见的儿科肝癌,仍然是儿童死亡的重要原因. 虽然巴西幼儿死亡率稳定,但青少年死亡率显著下降,反映了全球趋势.
科学领域:
- 儿科瘤学 儿科瘤学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 肝母细胞瘤是一种罕见的儿科恶性瘤,占儿童癌症的1-2%.
- 尽管发病率低,但它是早期儿童癌症相关死亡的重要原因.
研究的目的:
- 从2008年到2023年,分析巴西儿童和青少年肝细胞母细胞瘤死亡率趋势.
- 将这些趋势与全球死亡率估计进行比较.
主要方法:
- 使用死亡率信息系统 (SIM/DATASUS) 和全球疾病负担研究数据的生态研究.
- 分析死亡率,时间趋势 (Prais-Winsten回归) 和年龄/性别差异 (基平方测试).
主要成果:
- 记录了267例肝母细胞瘤死亡病例;0-4岁儿童死亡率为66.7%;男性死亡率为61.4%.
- 幼儿死亡率没有显著的趋势,但15-19岁青少年的死亡率每年显著下降 (APC = -38.4%).
- 观察到区域差异,东南地区死亡人数最高. 全球估计显示,死亡率正在下降,特别是在5岁以下的儿童中.
结论:
- 肝母细胞瘤仍然是早期儿童死亡的关键原因.
- 巴西青少年肝母细胞瘤死亡率显著下降,与较小儿童的稳定率形成鲜明对比.
- 全球数据表明,随着时间的推移,与肝细胞瘤相关的死亡率逐渐减少.
相关概念视频
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
Pharmacokinetics in Pediatric Patients: Drug Metabolism
193
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
193
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


